Matsumoto K, Shiroyama T, Yamamoto Y, Miyake K, et al. Impact of the Treatment Line on the Risks and Benefits of Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer and Interstitial Lung Disease. Chest 2022;162:e67-e69.
PMID: 35809960